The FDA has approved methylnaltrexone (Relistor, Valeant and Progenics) tablets (450 mg once daily) for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain.
Valeant expects to commence sales of methylnaltrexone tablets in the United States in the third quarter of 2016.
Methylnaltrexone subcutaneous injection (12 and 8 mg) was approved in 2008 for the treatment of OIC in adults with advanced illness who are receiving palliative care and in 2014 for the